Sarepta Appoints Ex-Allergan Executive as CEO and President

Studying market data including diagrams

Sarepta Therapeutics, Inc. SRPT announced the appointment of Douglas S. Ingram as the new chief executive officer (CEO). He will also serve as the company's president and will also be a member of the board of directors.

Ingram has a cumulative experience of more than 20 years as an executive leader in the field of life sciences. No wonder, this played an instrumental role in his selection for the job. Most recently, Ingram served as president and chief executive officer of Chase Pharmaceuticals, which was acquired by Allergan, plc AGN in late 2016.

Shares of Sarepta were up 2.5% on Wednesday following the announcement of the news. This year, Sarepta's shares have surged 23.4% so far while the Zacks classified Biomed-Genetics industry has gained 8.8%.

Prior to the acquisition of Allergan by Actavis, plc in 2015, Ingram served the company in various capacities including its president.

Sarepta's first marketed drug Exondys 51 was launched last year in the U.S. Also, a marketing application is under review in the EU. Ingram's near-term priorities include successful commercialization of Exondys 51.

Ingram will also focus on the development of other candidates in the pipeline and various research collaborations to maintain Sarepta's leadership position in the treatment of Duchenne muscular dystrophy (DMD). The company currently has collaboration with Catabasis Pharmaceuticals, Inc. CATB to explore a combination-drug treatment approach for DMD.

Ingram will replace Sarepta's present CEO, Edward M. Kaye who, in April this year, informed the company of his intention to resign on Sep 20, upon the completion of his term.

Sarepta Therapeutics, Inc. Price and Consensus

Sarepta Therapeutics, Inc. Price and Consensus | Sarepta Therapeutics, Inc. Quote

Zacks Rank & Key Pick

Sarepta Therapeutics carries a Zacks Rank #2 (Buy). Another stock to consider in the health care sector is Regeneron Pharmaceuticals, Inc. REGN , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Regeneron's earnings per share estimates increased from $10.16 to $10.52 for 2017 and from $10.90 to $12.10, over the last 60 days. The company has delivered positive earnings surprises in two of the four trailing quarters with an average beat of 0.45%. Regeneron's shares have surged 39.8% so far this year.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Allergan PLC. (AGN): Free Stock Analysis Report

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report

Catabasis Pharmaceuticals, Inc. (CATB): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More